The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).
 
Josep M Llovet
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celsion; Eisai; Exelixis; Glycotest; Incyte; Lilly
Research Funding - Bayer Schering Pharma (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
Travel, Accommodations, Expenses - Bayer
 
Chia-Jui Yen
No Relationships to Disclose
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis
 
Yoon-Koo Kang
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly/ImClone; LSK Biopharma; Merck Serono; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - DAEHWA Pharmaceutical; LSK Biopharma
 
Masatoshi Kudo
Honoraria - Abbvie; Astellas Pharma; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Gilead Sciences; MSD; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Peter R. Galle
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Merck Sharp & Dohme; Sirtex Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme
Speakers' Bureau - Bayer; Ipsen; Lilly; Sirtex Medical
Research Funding - Bayer
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen
 
Eric Assenat
Honoraria - Bayer; Ipsen; Novartis; Sanofi; SERVIER; Sirtex Medical; Terasphere
Consulting or Advisory Role - Bayer; Ipsen; Novartis; Sanofi; SERVIER; Sirtex Medical; Terasphere
 
Marc Pracht
No Relationships to Disclose
 
Ho Yeong Lim
No Relationships to Disclose
 
Kun-Ming Rau
No Relationships to Disclose
 
Christophe Borg
Consulting or Advisory Role - Bayer; Roche; SERVIER
 
Jean-Baptiste Hiriart
Consulting or Advisory Role - Abbvie; Gilead Sciences
Expert Testimony - Bristol-Myers Squibb; Gilead Sciences; Intercept Pharmaceuticals; Novartis
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; Astellas Pharma; MSD; MSD
 
Bruno Daniele
Honoraria - Bayer; Eisai; Ipsen; Lilly
Consulting or Advisory Role - Eisai; Incyte; Ipsen; MSD
Speakers' Bureau - Bristol-Myers Squibb; Eisai
Travel, Accommodations, Expenses - Bayer; Celgene
 
Thomas Berg
Honoraria - Abbvie; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Intercept Pharmaceuticals; Janssen; Merck; Novartis; Roche
Consulting or Advisory Role - Abbvie; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Intercept Pharmaceuticals; Janssen; Merck; Novartis; Roche
Speakers' Bureau - Abbvie; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Intercept Pharmaceuticals; Janssen; Merck; Novartis; Roche
Research Funding - Abbvie; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Intercept Pharmaceuticals; Janssen; Merck; Novartis; Roche
 
Hyun Cheol Chung
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Nathalie Godinot
Employment - Lilly; Lilly (I)
Stock and Other Ownership Interests - Lilly; Lilly (I)
 
Chunxiao Wang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly; Novartis
 
Yanzhi Hsu
Employment - Lilly; Lilly (I)
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Patent pending
 
William R. Schelman
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Lilly; Merck; Novartis; Roche/Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)